DYAIDYADIC INTERNATIONAL INC

Nasdaq dyadic.com


$ 1.51 $ 0.05 (3.38 %)    

Monday, 01-Jul-2024 15:26:09 EDT
QQQ $ 481.07 $ 1.18 (0.25 %)
DIA $ 391.45 $ 0.61 (0.16 %)
SPY $ 544.47 $ 0.73 (0.14 %)
TLT $ 90.63 $ -0.04 (-0.04 %)
GLD $ 215.45 $ 0.18 (0.08 %)
$ 1.53
$ 1.45
$ 0.00 x 0
$ 0.00 x 0
$ 1.45 - $ 1.51
$ 1.19 - $ 2.67
215,750
na
44.73M
$ 0.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-29-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-29-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-30-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 03-30-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-27-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 watching-dyadic-international-zacks-small-cap-research-gives-stock-9-price-valuation

https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_07012024_DYAI_Vandermosten.pdf

 dyadic-international-and-proliant-health-and-biologicals-announce-recombinant-albumin-development-and-commercialization-partnership--dyadic-will-receive-an-upfront-milestone-payment-of-15m

Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), announced today that they have entered into a development and comm...

 dyadic-international-q1-eps-007-down-from-003-yoy-sales-33462k-down-from-97805k-yoy

Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.07) per share. This is a 133.33 percent decrease over losse...

 dyadic-international-q4-eps-008-misses-006-estimate-sales-68653k-miss-80000k-estimate

Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate o...

 earnings-scheduled-for-march-28-2024

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

 dyadic-publishes-c1-monoclonal-antibody-in-nonhuman-primate-study-in-nature-communications

The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhum...

 dyadic-announces-strategic-partnership-agreement-to-develop-affordable-rabies-prophylactics-and-vaccines-using-its-c1-cell-microbial-protein-production-platform

Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI...

 dyadic-announces-research-and-development-collaboration-agreement-with-global-biopharmaceutical-company-to-design-and-produce-recombinant-proteins-using-dyadics-c1-filamentous-fungal-based-microbial-protein-production-platform

Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI...

 dyadic-announces-top-line-results-from-its-successful-phase-1-clinical-trial-for-a-first-in-human-filamentous-fungal-based-vaccine-candidate-primary-endpoint-met

Primary endpoint metDemonstrated safety and reactogenicity of DYAI-100 recombinant proteinC1-cell produced antigen was both saf...

 hc-wainwright--co-reiterates-buy-on-dyadic-international-maintains-6-price-target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Dyadic International (NASDAQ:DYAI) with a Buy and maintains $6 ...